[{"id":"7152824f-51d6-434a-a17c-b34a21be5fde","acronym":"","url":"https://clinicaltrials.gov/study/NCT07037004","created_at":"2025-06-28T13:42:45.741Z","updated_at":"2025-06-28T13:42:45.741Z","phase":"Phase 2","brief_title":"Adding a Probiotic (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery","source_id_and_acronym":"NCT07037004","lead_sponsor":"City of Hope Medical Center","biomarkers":" CXCL8","pipe":"","alterations":" ","tags":["CXCL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cdactin-O (CBM588)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 05/04/2026","start_date":" 05/04/2026","primary_txt":" Primary completion: 05/04/2027","primary_completion_date":" 05/04/2027","study_txt":" Completion: 05/04/2027","study_completion_date":" 05/04/2027","last_update_posted":"2025-06-25"},{"id":"d584e751-e3f2-4908-bfb6-b7b21ee2e46f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595683","created_at":"2021-01-18T17:40:49.334Z","updated_at":"2025-02-25T16:08:08.537Z","phase":"Phase 2","brief_title":"Pembrolizumab and EDP1503 in Advanced Melanoma","source_id_and_acronym":"NCT03595683","lead_sponsor":"University of Chicago","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • EDP1503"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 10/02/2018","start_date":" 10/02/2018","primary_txt":" Primary completion: 11/02/2027","primary_completion_date":" 11/02/2027","study_txt":" Completion: 11/02/2027","study_completion_date":" 11/02/2027","last_update_posted":"2024-07-31"},{"id":"1ca94224-ed66-47bc-8cab-310f2e9452eb","acronym":"MET4-IO","url":"https://clinicaltrials.gov/study/NCT03686202","created_at":"2023-01-10T19:59:33.100Z","updated_at":"2024-07-02T16:35:14.483Z","phase":"Phase 2/3","brief_title":"Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy","source_id_and_acronym":"NCT03686202 - MET4-IO","lead_sponsor":"University Health Network, Toronto","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 11/30/2018","start_date":" 11/30/2018","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-15"},{"id":"06ab7f9b-1285-4ff7-8e07-6a4608ecb3c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03922035","created_at":"2024-02-22T20:26:04.668Z","updated_at":"2024-07-02T16:35:18.238Z","phase":"Phase 1","brief_title":"CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant","source_id_and_acronym":"NCT03922035","lead_sponsor":"City of Hope Medical Center","biomarkers":" TNFA • TNFRSF1A • TGFB1","pipe":"","alterations":" ","tags":["TNFA • TNFRSF1A • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cdactin-O (CBM588)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/18/2019","start_date":" 04/18/2019","primary_txt":" Primary completion: 12/24/2024","primary_completion_date":" 12/24/2024","study_txt":" Completion: 12/24/2024","study_completion_date":" 12/24/2024","last_update_posted":"2024-02-22"},{"id":"b12338e0-fa45-447b-8e22-dd27c2e163c2","acronym":"P30CA033572","url":"https://clinicaltrials.gov/study/NCT03829111","created_at":"2024-01-02T17:17:16.914Z","updated_at":"2024-07-02T16:35:24.804Z","phase":"Phase 1","brief_title":"CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer","source_id_and_acronym":"NCT03829111 - P30CA033572","lead_sponsor":"City of Hope Medical Center","biomarkers":" IL6 • CXCL8","pipe":"","alterations":" ","tags":["IL6 • CXCL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cdactin-O (CBM588)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/14/2019","start_date":" 05/14/2019","primary_txt":" Primary completion: 06/11/2024","primary_completion_date":" 06/11/2024","study_txt":" Completion: 06/11/2024","study_completion_date":" 06/11/2024","last_update_posted":"2024-01-01"},{"id":"6b3fd358-0eaf-4894-b112-d5bec4021ece","acronym":"","url":"https://clinicaltrials.gov/study/NCT05877430","created_at":"2023-05-26T15:07:03.626Z","updated_at":"2024-07-02T16:35:25.993Z","phase":"Phase 1/2","brief_title":"Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer","source_id_and_acronym":"NCT05877430","lead_sponsor":"CJ Bioscience, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • CJRB-101"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 09/11/2023","start_date":" 09/11/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2023-12-18"},{"id":"0f0997b4-e016-4774-9c8c-8817ae0fe8c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05462496","created_at":"2022-07-18T14:01:45.193Z","updated_at":"2024-07-02T16:35:28.767Z","phase":"Phase 2","brief_title":"Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer","source_id_and_acronym":"NCT05462496","lead_sponsor":"Icahn School of Medicine at Mount Sinai","biomarkers":" CD38 • IL2RA • CD69 • ISG20","pipe":"","alterations":" ","tags":["CD38 • IL2RA • CD69 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 03/13/2023","start_date":" 03/13/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-11-18"},{"id":"06ceeccc-7d55-46ab-9d6e-8f12f9fbc6ba","acronym":"PICASSO","url":"https://clinicaltrials.gov/study/NCT04988841","created_at":"2021-08-04T14:53:06.476Z","updated_at":"2024-07-02T16:35:35.795Z","phase":"Phase 2","brief_title":"Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma","source_id_and_acronym":"NCT04988841 - PICASSO","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" IL6 • ISG20","pipe":"","alterations":" ","tags":["IL6 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Xervyteg (MaaT013)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/20/2022","start_date":" 01/20/2022","primary_txt":" Primary completion: 01/20/2024","primary_completion_date":" 01/20/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-09-26"},{"id":"07560d1e-9bca-447e-ad00-00b14999bb00","acronym":"PROMOTE-HN","url":"https://clinicaltrials.gov/study/NCT05743777","created_at":"2023-02-24T16:01:28.995Z","updated_at":"2024-07-02T16:35:47.629Z","phase":"Phase 2","brief_title":"PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT05743777 - PROMOTE-HN","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/12/2023","start_date":" 05/12/2023","primary_txt":" Primary completion: 05/12/2023","primary_completion_date":" 05/12/2023","study_txt":" Completion: 05/12/2023","study_completion_date":" 05/12/2023","last_update_posted":"2023-05-18"}]